ABCG2 and breast cancer: The combination of sulbactam and doxorubicin can enhance the cytotoxicity of doxorubicin in the breast cancer cells by inhibiting the transcription and initiation of translation associated proteins and ABC transporters, reducing their expression, and blocking the efflux of doxorubicin, thus triggering apoptosis in the breast cancer cells.